<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Veselka, Josef</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term Euro-ASA Registry Data</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-10-21 10:14:30</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-13</style></pages><abstract><style  face="normal" font="default" size="100%">Alcohol septal ablation (ASA) performed in dedicated centers is a safe and effective procedure for highly symptomatic obstructive hypertrophic cardiomyopathy patients. The post-ASA residual obstruction is a significant factor influencing long-term functional status and survival. Appropriate pre-procedural patient selection and elimination of the left ventricular outflow obstruction should be pursued in these patients.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>